Journal Information
Vol. 25. Issue 2.
Pages 65-68 (March 1989)
Share
Share
Download PDF
More article options
Vol. 25. Issue 2.
Pages 65-68 (March 1989)
Full text access
Comparacion entre procaterol y salbutamol mediante dosis-respuesta acumulada en pacientes con limitacion cronica al flujo aereo
Comparison between procaterol and salbutamol by means of cumulative dose-response in patients with chronic limitation to airflow
Visits
5695
M. Mayos, M. González, P. Casán, J. García-Barbal, J. Sanchís
Unitat de Funcíó Pulmonar. Hospital de la Santa Creu i Sant Pau. Barcelona
This item has received
Article information

El efecto broncodilatador de un nuevo adrenérgico beta-2 inhalado, el procaterol, se comparó con el salbutamol, mediante una técnica de dosis respuesta acumulada.

Se estudiaron 14 pacientes con limitación crónica al flujo aéreo y respuesta broncodilatadora significativa. El estudio se realizó en dos días consecutivos según diseño ciego simple. Cada día se administró al paciente 10 inhalaciones de uno u otro fármaco, repartidas en dos inhalaciones cada 10 min. La dosis de salbutamol (S) utilizada fue de 0,1mg/inh. con dosis máxima de 1mg y la de procaterol (P) de 0,01mg/ihn. con dosis máxima de 0,1mg. Tres pacientes fueron excluidos por excesiva variación de su espirometría basal durante el estudio y uno por problemas en la administración del aerosol.

El incremento del FEV1 en los primeros 10 min, expresado en porcentaje ponderado sobre el valor basal, fue de 28 SD15% con S y 24 SD17% con P (NS). El incremento máximo fue de 44 SD18% con S y de 41 SD19% con P (NS). Este efecto máximo se alcanzó entre la cuarta y quinta dosis. El incremento alcanzado a los 10 min en relación al máximo fue de 59 SD20% con S y de 46 SD27% con P (NS). En el resto de parámetros espirométricos tampoco hubo diferencias significativas.

En resumen, el procaterol logró un efecto broncodilatador similar al salbutamol. En ambos casos, los resultados obtenidos con la administración acumulativa de fármaco apoyan la posibilidad de aumentar las dosis habitualmente recomendadas para uso clínico de beta-2 en aerosol.

The effect of a new inhaled beta-2-adrenergic drug, procaterol, was compared with that of salbutamol by means of a cumulative dose-response technique.

Fourteen patients with chronic limitation to the airflow and significant bronchodilator response were evaluated. The study was caried out in two consecutive days with a single blind design. Each day, the patient received ten inhalations of either one or the other drug, distributed in two inhalations every 10 minutes. The salbutamol (S) dose was 0,1mg/inhalation, with a maximal dose of 1mg, and that of procaterol (P) was 0,01mg/inhalation, with a maximal dose of 0,1mg. Three patients were excluded because an excessive variation of their baseline spirometric values, and because of problems in the administration of the aerosol.

The increase of FEV1 in the initial 10 minutes, expressed as a weighted percent value of the baseline value, was 28% (SD 15) with S, and 41% (SD 19) with P (NS). The maximal increase was 44% (SD 18) with S and 41% (SD 19) with P (NS). This maximal effect was achieved between the fourth and fifth doses. The maximal increase achieved after 10 minutes as related with the maximal value was 59% (SD 20) with S and 46% (SD 27) with P (NS). In the remaining spirometric parameters there were not significant differences either.

To summarize, procaterol achieved a bronchodilator effect similar to that of salbutamol. In both cases, the results with the cumulative administration of the drug favor the possibility to increase the usually recommended doses for the clinical use of beta-2-adrenergic agents in aerosol.

Full text is only aviable in PDF
Bibliografía
[1.]
American Thoracic Society.
Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and Asthma, 136 (1987), pp. 225-243
[2.]
P.J. Barnes, C.B. Basbaum, J.A. Nadel.
Autoradiographic localization of autonomic receptors in airway smooth muscle. Marqued differences between large and small airways.
Am Rev Respir Dis, 127 (1983), pp. 758-762
[3.]
Raaijmakers JAM, van Rozen AJ, Kreukniet J. beta-adrenoceptors and chronic obstructive lung disease. 23rd Annual Meeting SEPCR Athens, June 20-24 1988.
[4.]
K. Svedmyr.
Beta-2 adrenoceptor stimulants and theophylline in asthma therapy.
Eur J Respir Dis, 62 (1981), pp. 234-255
[5.]
K.F. Chung, P.J. Barnes.
Respiratory and allergic disease.
I B Med J, 296 (1988), pp. 29-32
[6.]
S.P. Newman, S.W. Clarke.
Therapeutic aerosols I-Physical and practical considerations.
Thorax, 39 (1983), pp. 881-886
[7.]
S. Yoshizaki, K. Tanimura, S. Tamada, Y. Yabuuchi, K. Nakagawa.
Sympathomimetic amines having a carbostiryl nucleus.
J Med Chen, 19 (1976), pp. 1138-1142
[8.]
Y. Yabuuchi, S. Yamashita, S. Tet.
Pharmacological studies of OPC-2009, a newly synthetized selective beta-adrenoceptor stimulant in the bronchomotor and cardiovascular systems of the anesthetized dogs.
J Pharmacol Exp Ther, 202 (1977), pp. 326-336
[9.]
J. Britton, A. Tattersfield.
Comparison of cumulative and non-cumulative techniques to measure dose-response curves for beta-agonists in patients with asthma.
Thorax, 39 (1984), pp. 597-599
[10.]
Sociedad Española de Patología del Aparato Respiratorio.
Grupo de trabajo para la práctica de la espirometría en clínica.
Normativa para la espirometría forzada. Recomendaciones SEPAR n 1, Ed. Doyma, (1984),
[11.]
R.W. Dal Negro, O. Zoccatelli, C. Pomari, P. Turco, P. Monici Pretti.
Protection against non-specific bronchial hyperreactivity and bronchodilating action of procaterol in atopics.
Int J Clin Pharm Ther Tox, 24 (1986), pp. 323-325
[12.]
J.A. Crespo, E. Garnacho, P. Ansola, J.M. Antoñana, V. Sobradillo.
Estudio comparativo del procaterol con salbutamol en inhalación a dosis única.
Arch Bronconeumol, 24 (1988), pp. 50-51
[13.]
R.J. Alliot, B.D. Lang, D.R.W. Rawson, W.J.H. Lechie.
Effects of salbutamol and isoprenaline phenilephrine in reversible airways obstruction.
Br Med J, (1972), pp. 539-542
[14.]
J.G. Prior, G.M. Cochrane.
Assessment of optimum dose of inhaled terbutaline in patients with chronic asthma: the use of simple cumulative dose-response curves.
Br J Dis Chest, 76 (1982), pp. 266-268
[15.]
S.J.B. Connellan, R.S.E. Wilson.
Nebulized salbutamol in adult asthma.
Lancet, 1 (1978), pp. 662
[16.]
J.F.J. Morrison, S.B. Pearson.
Dose-response study of metered dose inhaler (MDI) salbutamol in chronic stable asthma.
Thorax, 43 (1988), pp. 249
[17.]
G.M. Shenfield, J.W. Paterson.
Clinical assessment of bronchodilator drugs delivered by aerosol.
Thorax, 28 (1973), pp. 124-128
[18.]
P.A. Corris, E. Neville, S. Nariman, G.J. Gibson.
Dose-response study of inhaled salbutamol powder in chronic airflow obstruction.
Thorax, 38 (1983), pp. 292-296
[19.]
S.C. Jenkins, J. Moxham.
High dose salbutamol in chronic bronchitis. Comparison of 400 mcg, 1mg, 1,6mg, 2mg and placebo delivered by Rotahaler.
Br J Dis Chest, 81 (1987), pp. 242-247
[20.]
R.E. Ruffin, G. Obminski, M.F. Newhouse.
Aerosol salbutamol administration by IPPB: lowest effective dose.
Thorax, 33 (1978), pp. 684-693
[21.]
Y.F.J. Choo-Kang, W.T. Simpson, I.W.B. Grant.
Controlled comparison of the bronchodilator effects of three beta-adrenergic stimulant drugs administered by inhalation to patients with asthma.
Br Med J, (1969), pp. 286-289
[22.]
E. Codina, R. Miralda, P. Casán, J. Sanchís.
Rapidez de la broncodilatación por aerosol beta-2 adrenérgico.
Arch Bronconeumol, 23 (1987), pp. 37
[23.]
J.E. Agnew, D. Pavia, S.W. Clarke.
Airways penetration of inhaled radioaerosol: an index to small airways function?.
Eur J Respir Dis, 62 (1981), pp. 239-255
[24.]
M.H. Williams, C. Kane.
Dose response of patients with asthma to inhaled isoproterenol.
Am Rev Respir Dis, 111 (1975), pp. 321-324
[25.]
M.I. Ullah, G.B. Newman, K.B. Saunders.
Influence of age on response to ipratropium and salbutamol in asthma.
Thorax, 36 (1981), pp. 523-529
Copyright © 1989. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?